Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Q32 Bio Inc. (QTTB : NSDQ)

• Company Description    Q32 Bio Inc. is a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis. Q32 Bio Inc., formerly known as Homology Medicines Inc., is based in WALTHAM, Mass. Number of Employees: 24

• Price / Volume Information    Yesterday's Closing Price: $5.80 Daily Weekly Monthly 20 Day Moving Average: 250,885 shares Shares Outstanding: 16.96 (millions) Market Capitalization: $98.34 (millions) Beta: -0.05 52 Week High: $8.05 52 Week Low: $1.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.49% -14.87% 12 Week 21.85% 12.64% Year To Date 74.70% 52.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 830 WINTER STREET - WALTHAM,MA 02451 USA ph: 781-999-0232 fax: - q32bio@argotpartners.com http://www.q32bio.com

• General Corporate Information    Officers Jodie Morrison - Chief Executive Officer and Director Lee Kalowski - Chief Financial Officer and President David Grayzel - Director Diyong Xu - Director Isaac Manke - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 746964105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 16.96 Most Recent Split Date: 3.00 (0.06:1) Beta: -0.05 Market Capitalization: $98.34 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.57 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.02 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 3.35 PEG Ratio: - Price Ratios Price/Book: 2.12 Price/Cash Flow: 3.83 Price / Sales: - EPS Growth vs. Year Ago Period: 40.00% vs. Previous Quarter: -114.79% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - 149.23 12/31/25 - 988.60 09/30/25 - - ROA 03/31/26 - 34.50 12/31/25 - 27.32 09/30/25 - -57.02 Current Ratio 03/31/26 - 5.36 12/31/25 - 4.85 09/30/25 - 4.57 Quick Ratio 03/31/26 - 5.36 12/31/25 - 4.85 09/30/25 - 4.57 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - 61.86 12/31/25 - 55.49 09/30/25 - - Book Value 03/31/26 - 2.73 12/31/25 - 3.41 09/30/25 - -1.50 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.04 12/31/25 - 0.08 09/30/25 - - Debt-to-Capital 03/31/26 - 4.02 12/31/25 - 7.64 09/30/25 - -

Powered by Zacks Investment Research ©